Last reviewed · How we verify

moxifloxacin 0.5% HCI ophthalmic solution

Allergan · FDA-approved active Small molecule

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.

Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death. Used for Bacterial conjunctivitis, Bacterial corneal ulcer, Prophylaxis of bacterial infection following ocular surgery.

At a glance

Generic namemoxifloxacin 0.5% HCI ophthalmic solution
Also known asVigamox®
SponsorAllergan
Drug classFluoroquinolone antibiotic
TargetBacterial DNA gyrase and topoisomerase IV
ModalitySmall molecule
Therapeutic areaOphthalmology / Infectious Disease
PhaseFDA-approved

Mechanism of action

As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and transcription. This dual inhibition leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative ocular pathogens. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: